A citation-based method for searching scientific literature

Joyce O'Shaughnessy, Christine Brezden-Masley, Marina Cazzaniga, Tapashi Dalvi, Graham Walker, James Bennett, Shozo Ohsumi. Breast Cancer Res 2020
Times Cited: 11







List of co-cited articles
63 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
375
45


Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
36

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Andrew N J Tutt, Judy E Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña,[...]. N Engl J Med 2021
280
36

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
J K Litton, S A Hurvitz, L A Mina, H S Rugo, K-H Lee, A Gonçalves, S Diab, N Woodward, A Goodwin, R Yerushalmi,[...]. Ann Oncol 2020
95
36

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, M S Aapro, F André, C H Barrios, J Bergh, G S Bhattacharyya, L Biganzoli,[...]. Ann Oncol 2020
359
36

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
899
36

Genomic characterization of metastatic breast cancers.
François Bertucci, Charlotte K Y Ng, Anne Patsouris, Nathalie Droin, Salvatore Piscuoglio, Nadine Carbuccia, Jean Charles Soria, Alicia Tran Dien, Yahia Adnani, Maud Kamal,[...]. Nature 2019
305
27

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Serena Nik-Zainal, Helen Davies, Johan Staaf, Manasa Ramakrishna, Dominik Glodzik, Xueqing Zou, Inigo Martincorena, Ludmil B Alexandrov, Sancha Martin, David C Wedge,[...]. Nature 2016
27

Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
C Winter, M P Nilsson, E Olsson, A M George, Y Chen, A Kvist, T Törngren, J Vallon-Christersson, C Hegardt, J Häkkinen,[...]. Ann Oncol 2016
76
27

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
27

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Javier Cortes, David W Cescon, Hope S Rugo, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H Barrios, Esther Holgado,[...]. Lancet 2020
474
27

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Véronique Diéras, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L Puhalla, Igor Bondarenko, Mario Campone, Erik H Jakobsen,[...]. Lancet Oncol 2020
107
27

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Nadine M Tung, Mark E Robson, Steffen Ventz, Cesar A Santa-Maria, Rita Nanda, Paul K Marcom, Payal D Shah, Tarah J Ballinger, Eddy S Yang, Shaveta Vinayak,[...]. J Clin Oncol 2020
134
27

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Matthew P Goetz, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch-Shimon, Jens Huober, In Hae Park, Olivier Trédan, Shin-Cheh Chen, Luis Manso,[...]. J Clin Oncol 2017
723
27

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
A Gennari, F André, C H Barrios, J Cortés, E de Azambuja, A DeMichele, R Dent, D Fenlon, J Gligorov, S A Hurvitz,[...]. Ann Oncol 2021
103
27

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
27

PARP inhibitor resistance: the underlying mechanisms and clinical implications.
He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang. Mol Cancer 2020
110
18

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
18

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
Dalibor Blazek, Jiri Kohoutek, Koen Bartholomeeusen, Eric Johansen, Petra Hulinkova, Zeping Luo, Peter Cimermancic, Jernej Ule, B Matija Peterlin. Genes Dev 2011
296
18


A decade of clinical development of PARP inhibitors in perspective.
J Mateo, C J Lord, V Serra, A Tutt, J Balmaña, M Castroviejo-Bermejo, C Cruz, A Oaknin, S B Kaye, J S de Bono. Ann Oncol 2019
223
18

Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Victor Quereda, Simon Bayle, Francesca Vena, Sylvia M Frydman, Andrii Monastyrskyi, William R Roush, Derek R Duckett. Cancer Cell 2019
108
18

Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.
Kathleen E Malone, Janet R Daling, David R Doody, Li Hsu, Leslie Bernstein, Ralph J Coates, Polly A Marchbanks, Michael S Simon, Jill A McDonald, Sandra A Norman,[...]. Cancer Res 2006
227
18

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
18

Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Zora Baretta, Simone Mocellin, Elena Goldin, Olufunmilayo I Olopade, Dezheng Huo. Medicine (Baltimore) 2016
99
18

BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Shoshana M Rosenberg, Kathryn J Ruddy, Rulla M Tamimi, Shari Gelber, Lidia Schapira, Steven Come, Virginia F Borges, Bryce Larsen, Judy E Garber, Ann H Partridge. JAMA Oncol 2016
79
18

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010
18

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, Suet-Feung Chin, Gulisa Turashvili, Oscar M Rueda, Mark J Dunning, Doug Speed, Andy G Lynch, Shamith Samarajiwa, Yinyin Yuan,[...]. Nature 2012
18

The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.
Lindsay Angus, Marcel Smid, Saskia M Wilting, Job van Riet, Arne Van Hoeck, Luan Nguyen, Serena Nik-Zainal, Tessa G Steenbruggen, Vivianne C G Tjan-Heijnen, Mariette Labots,[...]. Nat Genet 2019
143
18

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
M Esteller, J M Silva, G Dominguez, F Bonilla, X Matias-Guiu, E Lerma, E Bussaglia, J Prat, I C Harkes, E A Repasky,[...]. J Natl Cancer Inst 2000
854
18

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
311
18

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms, Paula Proszek, Michael Hubank, Mitch Dowsett, Andrew Dodson, Frances Daley,[...]. Nat Commun 2020
95
18


Replication fork stability confers chemoresistance in BRCA-deficient cells.
Arnab Ray Chaudhuri, Elsa Callen, Xia Ding, Ewa Gogola, Alexandra A Duarte, Ji-Eun Lee, Nancy Wong, Vanessa Lafarga, Jennifer A Calvo, Nicholas J Panzarino,[...]. Nature 2016
475
18

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
404
18

Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
Johan Staaf, Dominik Glodzik, Ana Bosch, Johan Vallon-Christersson, Christel Reuterswärd, Jari Häkkinen, Andrea Degasperi, Tauanne Dias Amarante, Lao H Saal, Cecilia Hegardt,[...]. Nat Med 2019
117
18

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
363
18

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts,[...]. Nat Med 2017
473
18

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
E L Mayer, V Abramson, R Jankowitz, C Falkson, P K Marcom, T Traina, L Carey, M Rimawi, J Specht, K Miller,[...]. Ann Oncol 2020
29
18

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Kirsten M Timms, Victor Abkevich, Elisha Hughes, Chris Neff, Julia Reid, Brian Morris, Saritha Kalva, Jennifer Potter, Thanh V Tran, Jian Chen,[...]. Breast Cancer Res 2014
219
18

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.
Bernard Pereira, Suet-Feung Chin, Oscar M Rueda, Hans-Kristian Moen Vollan, Elena Provenzano, Helen A Bardwell, Michelle Pugh, Linda Jones, Roslin Russell, Stephen-John Sammut,[...]. Nat Commun 2016
846
18

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Mark Robson, Kathryn J Ruddy, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Wei Li, Nadine Tung, Anne Armstrong,[...]. Eur J Cancer 2019
36
18

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Nicholas C Turner, Melinda L Telli, Hope S Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A Mina, Judith Balmaña, Peter A Fasching, Sara A Hurvitz,[...]. Clin Cancer Res 2019
70
18

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
Solene De Talhouet, Julien Peron, Aurelie Vuilleumier, Alex Friedlaender, Valeria Viassolo, Aurélie Ayme, Alexandre Bodmer, Isabelle Treilleux, Noemie Lang, Jean- Christophe Tille,[...]. Sci Rep 2020
36
18


Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
P A Fasching, T Link, J Hauke, F Seither, C Jackisch, P Klare, S Schmatloch, C Hanusch, J Huober, A Stefek,[...]. Ann Oncol 2021
51
18

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
A G Waks, O Cohen, B Kochupurakkal, D Kim, C E Dunn, J Buendia Buendia, S Wander, K Helvie, M R Lloyd, L Marini,[...]. Ann Oncol 2020
68
18

A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
Jenna M Collins, Beth L Nordstrom, Kimmie K McLaurin, Tapashi B Dalvi, Susan C McCutcheon, James C Bennett, Brian R Murphy, Puneet K Singhal, Charles McCrea, Reshma Shinde,[...]. Oncol Ther 2021
9
22

The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.
Thomas P Slavin, Kara N Maxwell, Jenna Lilyquist, Joseph Vijai, Susan L Neuhausen, Steven N Hart, Vignesh Ravichandran, Tinu Thomas, Ann Maria, Danylo Villano,[...]. NPJ Breast Cancer 2017
82
18


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.